The decision about whether to start a child on ADHD medication is one of the harder conversations in paediatric care. The internet provides confident answers in both directions, and the available information varies in quality. This article covers what the evidence actually shows, what the medication does and does not do, the side effects worth planning around, and how to think about the decision in your particular child's case. It is written for parents and is decision-support, not a recommendation in either direction.
What NICE NG87 actually says
NICE NG87 sets out the UK approach to ADHD medication in children [1]. For children under 5, NICE does not recommend medication except in specialist circumstances; non-pharmacological support is the first line.
For children aged 5 and over, the position is:
- Medication is offered to children whose ADHD symptoms are causing significant impairment after environmental modifications and parenting support have been tried
- Medication is offered earlier where the impairment is more severe
- Methylphenidate is the usual first-line stimulant for children and adolescents
- Lisdexamfetamine (Elvanse) is usually second-line, although clinical judgement allows reordering
- Atomoxetine (Strattera) and guanfacine (Intuniv) are non-stimulant alternatives where stimulants are unsuitable, not tolerated, or have not worked
NICE specifies that medication initiation must be by a specialist with training in paediatric ADHD prescribing [1]. This is the same standard that applies to NeuroFX's ADHD medication and prescribing with NeuroFX pathway.
What the medication actually does
Stimulants increase the availability of two neurotransmitters in the brain: dopamine and noradrenaline. Both are involved in attention, working memory, motivation and the regulation of behaviour. The ADHD brain shows differences in dopamine and noradrenaline signalling, and stimulants partially correct those differences for the duration the medication is active [5].
In children, when the medication is working, parents and teachers commonly describe:
- The child can sit and complete a task they previously could not finish
- Less impulsive interrupting and turn-taking difficulty
- Less emotional reactivity to small frustrations
- A child who is "more themselves" rather than a "different child"
- School reports that note specific improvements in focus, behaviour and academic engagement
The medication does not change a child's personality. The effect is on the regulation systems that the ADHD brain has difficulty with. Children often describe it as feeling like they can "think before doing", "hear what people are saying", or "finish what they started".
What the medication does not do
A few important things the medication does not do:
- It does not improve intellectual ability. A child who is bright will be more able to demonstrate that ability; the underlying intelligence is not affected.
- It does not address every difficulty. Anxiety, mood, social skills, learning difficulties and family stress all need their own attention.
- It does not work for every child. Around a third of children find their first stimulant is not the right fit; switching often produces a working option [4].
- It does not last beyond the active medication window. A typical school-age modified-release stimulant covers most of the school day; evenings and weekends are usually not covered unless additional doses are prescribed.
- It does not cure ADHD. It manages the symptoms while it is being taken; the underlying neurotype remains.
What the evidence shows on benefit
The 2018 Cortese et al. network meta-analysis in the Lancet Psychiatry is the largest synthesis of ADHD medication trials [4]. The headline findings for children and adolescents:
- Stimulants are more effective than non-stimulants and substantially more effective than placebo
- Methylphenidate is the best-tolerated first-line option in children and adolescents
- Effect sizes for stimulants on ADHD symptoms are large by the standards of psychiatric medication
- Real-world response is generally consistent with trial findings, with most children seeing meaningful improvement
Long-term outcome studies are more mixed. Stimulants reliably improve symptoms while being taken; the question of whether long-term outcomes (academic attainment, mental health, accidents, substance use) are improved by long-term medication is more nuanced and depends on which outcome is being measured. The 2021 Faraone et al. consensus statement summarises the evidence: medication is one important component of treatment, but it is not the whole picture [5].
The side effects worth planning around
The BNFc lists the common side effects of stimulants in children [2, 3]:
- Reduced appetite, particularly at lunchtime, often the most consistently reported effect
- Difficulty getting to sleep, especially in the first one to two weeks of a new dose
- Mild headache, usually transient
- A small rise in heart rate and blood pressure
- Occasional irritability or mood flattening as the dose wears off in late afternoon
- Slowed growth in weight, and sometimes height, which usually returns to expected trajectory after the medication is stopped
Most early effects settle within two weeks. Persistent or significant effects warrant a conversation with the prescriber and may prompt a dose adjustment, a formulation change, or a switch.
A more thorough run-through is in a calm guide to the first six months on stimulants and the dedicated stimulant side effects article in this library.
How to think about the decision in your particular child's case
The decision is not abstract. It depends on your child. Several questions help [1, 5]:
How impaired is your child?
If the ADHD-related difficulties are seriously affecting school, friendships, family life and self-esteem, the threshold for trying medication is lower. If the difficulties are mild and the child is generally coping, the threshold is higher.
What have you already tried?
NICE NG87 recommends environmental modifications and parenting support before medication, particularly in milder cases. If structured support has been in place and the difficulties remain significant, that strengthens the case for medication.
What does your child think?
For older children and adolescents, their view matters substantially. A child who does not want to take medication, or who does not understand why, is far less likely to engage with the trial. Honest conversation, age-appropriately, is part of the preparation.
What is the school picture?
A child whose teachers describe significant impairment in class, who is falling behind academically despite ability, or whose behaviour is leading to escalating consequences will often benefit substantially from medication. This is what the medication is most reliably useful for.
What are your concerns?
Many parents have specific concerns: side effects, the idea of medicating a child, social or extended-family disapproval, long-term effects. These are legitimate questions and deserve honest answers from the prescriber. A good prescribing pathway addresses your particular concerns rather than dismissing them.
The trial itself
If you decide to try medication, what to expect:
- A specialist consultation to confirm the prescribing decision and choose a starting medication
- Baseline measurements (height, weight, blood pressure, heart rate)
- A low starting dose, with planned dose increases every one to two weeks where benefit is incomplete and tolerability is good
- A formal review at around six weeks once a steady working dose is reached [1]
- Continuing review at three months and then at agreed intervals
- Growth and cardiovascular monitoring at each review
The trial usually takes around three months to reach a stable working dose. Around a third of children find the first stimulant is not the right fit and switch to another. Most children find a working option in two trials [4].
ADHD diagnosis is more than medication makes the broader case. Medication is one tool; the support package is wider.
What this means in practice
- NICE NG87 supports medication in children aged 5 and over where ADHD symptoms are causing significant impairment.
- Methylphenidate is usually first-line in children; lisdexamfetamine is usually second-line.
- The medication does not change personality. It supports the regulation systems the ADHD brain has difficulty with for the duration the medication is active.
- Around a third of children find the first stimulant is not the right fit; switching usually produces a working option.
- Common side effects (appetite, sleep, mood) mostly settle within two weeks; the prescriber adjusts where they do not.
- The decision is your child's, your family's, and the prescriber's, not the internet's.
When to speak to a professional
Speak to your GP or your specialist prescriber about whether medication is appropriate for your child. NHS routes for paediatric ADHD assessment and prescribing exist; NeuroFX offers private ADHD assessment for children aged 6 and upwards and specialist prescribing under NICE NG87 where the NHS wait is not workable. Seek urgent help via 111, 999 or A&E for any acute mental health crisis or significant safety concern.
Sources
- NICE. Attention deficit hyperactivity disorder: diagnosis and management. NG87. National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ng87
- British National Formulary for Children. Methylphenidate hydrochloride. https://bnfc.nice.org.uk/drugs/methylphenidate-hydrochloride/
- British National Formulary for Children. Lisdexamfetamine mesilate. https://bnfc.nice.org.uk/drugs/lisdexamfetamine-mesilate/
- Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit/hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727-738.
- Faraone SV, Banaschewski T, Coghill D, et al. The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder. Neuroscience and Biobehavioral Reviews. 2021;128:789-818.
